ClinicalTrials.Veeva

Menu

Dysferlinopathy Protein in Peripheral Blood Monocytes.

F

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Status

Completed

Conditions

Limb-Girdle Muscular Dystrophy Type 2B
Distal Myopathy With Anterior Tibial Onset
Muscular Dystrophies
Miyoshi Myopathy

Treatments

Diagnostic Test: Protein analysis

Study type

Observational

Funder types

Other

Identifiers

NCT06507215
IIBSP-MON-2011-157

Details and patient eligibility

About

The objective of the study is to answer the following important questions. Deficiency of the dysferlin protein is the cause of a very rare limb-girdle muscular dystrophy (LGMD-2B) that leads to significant disability. This disease is caused by mutations in the dysferlin gene. It is a recessive inherited disease, meaning that both copies of the gene must have mutations for the disease to develop. This study aims to analyze the frequency of carriers of a mutation in the DYSF gene in the Caucasian population. To achieve this, The investigator analyzed the blood of 100 healthy volunteers from their local area, quantifying the dysferlin protein in peripheral blood monocytes.

Enrollment

149 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Individuals diagnosed with dysferlinopathies.
  • Carriers of a single mutation in the DYSF gene.
  • Participants who are willing to undergo treatment with oral vitamin D3.
  • Subjects who can provide informed consent for participation in the study.
  • Controls and carriers willing to participate in in vitro studies using HL60 cells, monocytes, and myotubes.

Exclusion criteria

  • Individuals with conditions or medications that could interfere with the study outcomes of dysferlin expression.
  • Participants who are unwilling or unable to adhere to the study protocol for the duration of the study period.
  • Pregnant or breastfeeding women.
  • Individuals with known allergies or adverse reactions to vitamin D3 supplements.
  • Subjects with severe concurrent illnesses that may impact the study's objectives or their ability to participate effectively.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems